Telix Pharmaceuticals Limited (NASDAQ:TLX) Stock Has Average Price Target of $20.50 According to Brokerages

Telix Pharmaceuticals Limited (NASDAQ:TLX) has received an average rating of “Buy” from the six analysts that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation, four have given a buy recommendation and one has assigned a strong buy recommendation to the company. The average twelve-month target price among brokers that have updated their coverage on the stock in the last year is $20.50.

A number of brokerages have issued reports on TLX. Citigroup reaffirmed a “buy” rating on shares of Telix Pharmaceuticals in a report on Thursday, August 20th. Weiss Ratings upgraded shares of Telix Pharmaceuticals from a “sell (d)” rating to a “hold (c-)” rating in a research report on Friday, August 21st. Wedbush reaffirmed an “outperform” rating and set a $22.00 target price on shares of Telix Pharmaceuticals in a research note on Wednesday, September 23rd. HC Wainwright reaffirmed a “buy” rating and set a $20.00 target price on shares of Telix Pharmaceuticals in a research note on Friday, September 25th. Finally, Royal Bank Of Canada upgraded shares of Telix Pharmaceuticals from a “hold” rating to a “moderate buy” rating in a report on Monday, September 21st.

Telix Pharmaceuticals Stock Performance

Shares of TLX opened at $10.55 on Monday. The business’s 50 day moving average is $11.40 and its 200 day moving average is $10.61. The company has a debt-to-equity ratio of 1.16, a current ratio of 2.01 and a quick ratio of 1.85. Telix Pharmaceuticals has a 12-month low of $6.28 and a 12-month high of $13.11.

Institutional Investors Weigh In On Telix Pharmaceuticals

Several large investors have recently made changes to their positions in TLX. Bank of America Corp DE boosted its stake in Telix Pharmaceuticals by 523.8% during the first quarter. Bank of America Corp DE now owns 10,031 shares of the company’s stock valued at $96,000 after buying an additional 8,423 shares during the last quarter. XY Capital Ltd purchased a new position in Telix Pharmaceuticals during the 1st quarter valued at approximately $120,000. Hennion & Walsh Asset Management Inc. bought a new stake in Telix Pharmaceuticals in the 2nd quarter worth approximately $1,731,000. Private Advisor Group LLC increased its stake in Telix Pharmaceuticals by 276.3% in the 1st quarter. Private Advisor Group LLC now owns 174,415 shares of the company’s stock worth $1,669,000 after acquiring an additional 128,070 shares during the last quarter. Finally, Lazard Asset Management LLC increased its stake in Telix Pharmaceuticals by 15.7% in the 1st quarter. Lazard Asset Management LLC now owns 289,917 shares of the company’s stock worth $2,775,000 after acquiring an additional 39,400 shares during the last quarter.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing and commercializing radiopharmaceuticals and molecularly targeted radiation products. Its technologies are designed to help identify disease through medical imaging and, in some cases, deliver radiation directly to targeted cancer cells.

The company’s primary commercial product is Illuccix (kit for the preparation of gallium-68 gozetotide injection), a positron emission tomography imaging agent used to identify prostate-specific membrane antigen-positive lesions in adults with prostate cancer.